Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) FCF Margin: 2022-2025

Historic FCF Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Sep 2025 value amounting to -1.77%.

  • Arcutis Biotherapeutics' FCF Margin rose 7606.00% to -1.77% in Q3 2025 from the same period last year, while for Sep 2025 it was -10.46%, marking a year-over-year increase of 11052.00%. This contributed to the annual value of -57.14% for FY2024, which is 35806.00% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported FCF Margin of -1.77% as of Q3 2025, which was down 685.70% from 0.30% recorded in Q2 2025.
  • Arcutis Biotherapeutics' FCF Margin's 5-year high stood at 3,106.58% during Q1 2022, with a 5-year trough of -9,338.07% in Q3 2022.
  • Moreover, its 3-year median value for FCF Margin was -77.83% (2024), whereas its average is -461.67%.
  • Over the last 5 years, Arcutis Biotherapeutics' FCF Margin had its largest YoY gain of 919,124bps in 2023, and its largest YoY loss of 599,856bps in 2023.
  • Quarterly analysis of 4 years shows Arcutis Biotherapeutics' FCF Margin stood at -2,404.19% in 2022, then skyrocketed by 198,832bps to -415.87% in 2023, then soared by 41,482bps to -1.05% in 2024, then spiked by 7,606bps to -1.77% in 2025.
  • Its last three reported values are -1.77% in Q3 2025, 0.30% for Q2 2025, and -47.06% during Q1 2025.